BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 13, 2013
View Archived Issues
Phase II clinical trial data presented for new monoclonal antibody for type 1 diabetes
Read More
Novel nonhuman primate model developed for HCV infection
Read More
Synergistic effects on cognition seen with ZSET-1446 and galantamine, rivastigmine and memantine
Read More
Agios Pharmaceuticals patents new IDH1 inhibitors for cancer
Read More
Chinese group synthesizes novel agents for cancer
Read More
Spinifex Pharmaceuticals designs novel angiotensin AT2 receptor antagonists
Read More
Scientists at Merck Patent divulge new GCN2 inhibitors
Read More
EnVivo Pharmaceuticals synthesizes new gamma-secretase modulators
Read More
T-VEC shows potential as a treatment option for melanoma patients in phase III trials
Read More
Biocon launches ALZUMAb in India
Read More
DengueCide receives FDA orphan drug designation
Read More
TherapeuticsMD begins phase I study of its vaginal estradiol suppository
Read More
University of Alberta collaborates with BGI Shenzhen on cancer screening technology
Read More
Shionogi profiles achievements of first quarter of fiscal 2013
Read More
Phase III Allovectin trial does not meet efficacy endpoints
Read More
Advanomics receives second grant for Adva-27a
Read More
Cardium Therapeutics reports on Excellagen potential in birth defects
Read More
Galectin Therapeutics' GR-MD-02 receives FDA fast track designation
Read More
Celldex Therapeutics expands phase II ReACT study in recurrent glioblastoma
Read More
Immunomedics advances solid tumor ADC programs to phase II
Read More
Tekmira Pharmaceuticals begins phase I/II TKM-PLK1 trial
Read More
First human implantation of map3 cellular allogeneic bone graft completed
Read More
Avanir Pharmaceuticals and Merck enter co-promotion agreement for Januvia
Read More
Maxygen's shareholders approve dissolution of the company
Read More